On the other hand, treatment with lenalidomide enabled the upregulation of PD-L1 expression on the surface of MM cells by IFN-γ, or rather enhanced PD-L1 expression in combination with IFN-γ (Figure 6A). The gene discussed is IFNG; the disease is Miyoshi myopathy.